Identifai Genetics provides an early‑stage, non‑invasive prenatal screening that analyzes fetal cell‑free DNA from a simple maternal blood draw in the first trimester. Their proprietary bioinformatics pipeline digitally isolates fetal DNA from the mixed maternal‑fetal sample, reconstructs the fetal genome at high resolution, and detects a wide range of genetic conditions—from single‑gene mutations to chromosomal anomalies—delivering a comprehensive clinical report for obstetricians and genetics specialists.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of newborns each year are affected by severe genetic diseases, yet existing non‑invasive prenatal screens detect fewer than 10% of known disorders and invasive tests are risky and performed late in pregnancy.
Solution
Identifai Genetics offers a comprehensive, early‑stage prenatal screening that analyzes fetal cell‑free DNA (cfDNA) from a simple maternal blood draw in the first trimester. Their proprietary bioinformatics pipeline digitally isolates fetal DNA from the mixed maternal‑fetal sample, reconstructs the fetal genome at high resolution, and identifies actionable variants ranging from single‑nucleotide mutations to large chromosomal anomalies. The result is a detailed genetic report that enables clinicians to assess a wide spectrum of inherited conditions without the need for invasive procedures. By combining deep sequencing with advanced data‑science algorithms, Identifai provides a non‑invasive test that expands coverage far beyond the limited set of conditions addressed by current screening methods.
Target Audience
Primary customers are obstetricians, maternal‑fetal medicine specialists, and clinical genetics laboratories seeking a non‑invasive, broad‑coverage prenatal test for pregnant patients.
Features
- First‑trimester maternal blood draw followed by high‑throughput sequencing of mixed cfDNA
- Computational separation of fetal DNA using proprietary digital isolation algorithms
- High‑resolution reconstruction of the fetal genome to detect single‑gene mutations and chromosomal abnormalities
- Automated variant calling and clinical interpretation delivered in a comprehensive genetic report
- Scalable cloud‑based analytics pipeline ensuring rapid turnaround and data security
- Validation through large‑scale clinical studies in partnership with leading medical centers and a major health‑service provider